← All CCS Flashcard Decks

Treatment Planning & Management Flashcards

7 cards from real CCS practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Treatment Planning & Management flashcards as text
  1. A patient with dilated cardiomyopathy (EF 22%) develops NYHA Class III symptoms despite maximally tolerated beta-blocker, ACE inhibitor, and MRA. Which agent should be added to further reduce mortality?

    Answer: Sacubitril/valsartan (replacing ACE inhibitor)

    Sacubitril/valsartan (ARNI) reduces CV death and HF hospitalizations more than enalapril alone (PARADIGM-HF) and should replace the ACE inhibitor in eligible symptomatic HFrEF patients.

  2. Which non-pharmacologic intervention has the strongest evidence for improving mortality in patients with obstructive sleep apnea and heart failure?

    Answer: Continuous positive airway pressure (CPAP)

    CPAP treats obstructive sleep apnea, improves EF, reduces sympathetic tone, and lowers blood pressure; ASV is contraindicated in HFrEF due to increased mortality (SERVE-HF).

  3. A patient post-PCI for NSTEMI is on aspirin and ticagrelor. After 12 months of DAPT without bleeding complications, what is the recommended next step?

    Answer: Switch to aspirin alone

    After 12 months of DAPT post-ACS/PCI, current guidelines recommend continued aspirin monotherapy indefinitely unless bleeding risk warrants reassessment.

  4. A patient with severe symptomatic mitral regurgitation (primary, degenerative) has preserved EF of 62% and LVESD of 43 mm. What management is recommended?

    Answer: Mitral valve repair or replacement surgery

    LVESD ≥40 mm in severe primary MR is a Class I indication for mitral valve surgery even with preserved EF, because ventricular dysfunction will progress without repair.

  5. Which drug reduces cardiovascular events in patients with established ASCVD and elevated triglycerides (≥150 mg/dL) despite statin therapy?

    Answer: Icosapentaenoic acid (IPE / Vascepa)

    The REDUCE-IT trial showed that icosapentaenoic acid (Vascepa) 4 g/day significantly reduced ischemic events in statin-treated patients with elevated triglycerides and ASCVD.

  6. A patient with cardiac tamponade shows pulsus paradoxus of 18 mmHg. What is the definitive acute treatment?

    Answer: Emergent pericardiocentesis

    Pericardiocentesis is the definitive treatment for cardiac tamponade; it immediately relieves pericardial pressure and restores cardiac output.

  7. A 45-year-old with hypertrophic cardiomyopathy (non-obstructive) and a first-degree relative who suffered sudden cardiac death is asymptomatic. What is the primary consideration in their management?

    Answer: ICD implantation based on risk stratification

    ICD implantation should be considered in HCM patients with risk factors for SCD, including family history of HCM-related sudden death, using validated risk models (e.g., HCM Risk-SCD).

Written and edited by , founder of Practice Test Geeks, with AI assistance. We have not yet matched this exam's facts to an official source, so confirm fees, dates and rules with the exam body. Editorial policy